glp-1 news nov 2025 November in review: breakthroughs, UPFs under fire, Novonesis advances healthy longevity glp-1 news today 2025 november

These interventions are used for restoring lost volume and for resuspending and repositioning facial soft tissues to create a smoother, natural, more youthful appearance

Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program

A head-to-head review of clinical studies determined that among available GLP-1 RAs, there were A1C reductions from 0.78% to 1.9%

Some patients experience nausea, constipation, or vomiting

Cited 2/3/16

[16] Microdosing Tirzepatide: The Single-Dose Barrier Microdosing tirzepatide (Mounjaro/Zepbound) is much harder